London (ots/PRNewswire) – A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50% (p=0.028; CI 0.27-0.93) in high risk patients with a 10-year Framingham risk score >20% [...]
Tag Archive > Cv Events
Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization
Paris (ots/PRNewswire) – Sanofi-aventis announced today that results from the RealiseAF (Real-life global survey evaluating patients with Atrial Fibrillation) registry show that control of atrial fibrillation (AF) (defined by the 2006 ACC/AHA/ESC AF guidelines as either sinus rhythm or AF with heart rate at rest less than or equal 80 bpm)[1] was not achieved in [...]
Takeda Responds to FDA Advisory Committee Recommendation
London, July 15, 2010 (ots/PRNewswire) – The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular (CV) safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda [...]
Video: Crestor(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study
Orlando, Florida, November 17 (ots/PRNewswire) – JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular (CV) events in women without established cardiovascular disease (CVD). In this new analysis of 6,801 women from the JUPITER study, rosuvastatin 20 mg reduced CV events by 46% in [...]
CRESTOR(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study
Orlando, Florida, November 17 (ots/PRNewswire) – JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular (CV) events in women without established cardiovascular disease (CVD). In this new analysis of 6,801 women from the JUPITER study, rosuvastatin 20 mg reduced CV events by 46% in [...]
CRESTOR(R) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER
Barcelona (ots/PRNewswire) – A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p
CRESTOR(R) is the First Statin to Reduce Risk of Blood Clots in Veins in a Large Prospective Randomised Study
Orlando, Florida (ots/PRNewswire) – – A New Analysis From the JUPITER Trial A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP). [...]
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
San Diego, California (ots/PRNewswire) – A new analysis from the JUPITER study presented today at the International Stroke Conference (ISC) in San Diego, California, describes details of the stroke data according to gender, ethnicity and baseline risk factors. This data adds to the primary analysis of the JUPITER study which demonstrated that CRESTOR® (rosuvastatin calcium) [...]
